[Loss of maternal measles antibodies acquired by vaccination against measles]. / Ztráta spalnickových materských protilátek získaných ockováním proti spalnickám.

The objective of the investigation was to assess whether children of mothers who acquired measles antibodies resp. immunity by vaccination are at least for the first six months of their life protected by maternal antibodies. A group of fifty pregnant women mean age 18 years incl. their umbilical blood and blood of their children, mostly 5-6 months after birth, were examined by the haemagglutination inhibition and immunoenzymatic test. The levels of measles antibodies were detected in 11 women immunized against measles in cca 1970 and in 26 revaccinated women mostly after 5 to 11 years. In once vaccinated mothers and their umbilical bloods the mean HI titres were 1:8.5 and 1:14 resp. and the mean EIA titres were 1:3600 and 1:3040 resp. As to the eight newborn children at the age of 5 and 6 months 6 children did not have any protective antibodies. In twice vaccinated women and their umbilical bloods the mean HI titre was 1:10 and 1:16.4 resp. and EIA titres were 1:2937 and 1:3784 resp. Of the 15 newborn infants at the age of 4 to 6 months 11 infants did not have any protective antibodies. In 8 mothers without vaccination records and their umbilical bloods the mean HI titre was 1:7.5 and 1:25.5 and mean EIA titres were 1:8229 and 1:7360 resp. In none of their children at the age of 6 months measles antibodies were found. The finding of the lack of protection in children older than 6 months stimulates further research of the problem.

Bacterial lysate (I.R.S. 19) applied intranasally in the prevention of acute respiratory diseases in children: a randomized double-blind study.

A controlled trial was undertaken to test I.R.S. 19 (a commercial intranasal spray) versus placebo in the prevention of acute respiratory diseases (ARD) in 825 maternity-school children in three cities; another control group of 327 children received neither I.R.S. 19 nor placebo. The spraying was done twice a day for a total of 20 spraying days in each child; sprayings were interrupted on weekends and during absence, the mean spraying period being 34 calendar days. During the 6-month study (1 November to 30 April) the children were monitored for ARD morbidity causing absence from school. A total of 1,585 such ARD cases occurred; their etiology was not investigated. The indices evaluated were: total duration of ARD-associated absence, ARD incidence, and mean duration of one illness. With the administration schedule used, I.R.S. 19 did not, in an overall evaluation, surpass placebo in any of these indices in either normal children or a subgroup of children with presumed enhanced ARD susceptibility.

Family incidence of type B hepatitis.

Family incidence of HBsAg-positive viral hepatitis was confirmed to be high. In 499 families with a type B viral hepatitis patient, type B viral hepatitis morbidity among 1116 contacts amounted to 2.24% within 6 months of the primary patients' hospitalization (being 188.2 times higher than semiannual morbidity of the population of the Czech Socialist Republic, CSR) and the prevalence of HBsAg amounted to 8.96% (being 22.4 times higher than among the population of CSR). On deducting positive findings at first blood samplings, which at least partially eliminated individuals who could themselves have been the source of infection for the first patient in each family, the rate for contact cases equalled 0.70% (58.8 times higher morbidity than among the population) and the rate for HBsAg prevalence equalled 2.50% (6.25 times higher than among the population). Among 917 members of 335 families where a case of HBsAg-negative viral hepatitis occured, 0.32% developed HBsAg-positive viral hepatitis within 6 months (26.8 times higher morbidity than population morbidity) and the HBsAg prevalence was 2.94% (7.35 greater than among the population). On deducting the first positive findings no clinical illness remained and HBsAg prevalence equalle 0.98% (2.45 times higher than among the population). The highest HBsAg prevalence was found among contacts aged 0-5 years (17.09% for the whole period, 3.41% after deducting first positive findings) and 40 years and over (10.82% and 3.39%, respectively). Type B viral hepatitis morbidity was again highest in the age groups of 0-5 years (5.12%) and 40 years and over (2.54%) for the whole period. On deducting first positive findings, the 40+ years group displayed the highest morbidity (1.27%), whereas the 0-5 years group displayed zero morbidity. Disclosure of the mechanisms of nonparenteral or inapparently parenteral transmission specific for family environments would be important for the prospect of introducing adequate measures to limit or prevent the spread of type B viral hepatitis.